Pharmacogenetics of the β2-Adrenergic Receptor Gene

Immunology and Allergy Clinics of North America

Volumn 27, Issue 4, 2007, Pages 665-684

  Ortega, Victor E ^a   Hawkins, Gregory A ^a   Peters, Stephen P ^a   Bleecker, Eugene R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; PLACEBO; SALBUTAMOL; SALMETEROL;

ASTHMA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG MECHANISM; ETHNIC AND RACIAL GROUPS; GENETIC POLYMORPHISM; HAPLOTYPE; HEREDITY; HUMAN; INFECTION CONTROL; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-AGONISTS; ANIMALS; ASTHMA; FORCED EXPIRATORY VOLUME; HUMANS; PEAK EXPIRATORY FLOW RATE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 35948965261     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2007.09.007     Document Type: Review

References (77)

1. Masoli M., Fabian D., Holt S., et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 (2004) 469-478
2. Drazen J.M., Silverman E.K., and Lee T.H. Heterogeneity of therapeutic responses in asthma. Br Med Bull 56 (2000) 1054-1070
3. Malmstrom K., Rodriguez-Gomez G., Guerra J., et al. Oral Montelukast, unhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 130 (1999) 487-495
4. Hawkins G.A., Weiss S.T., and Bleecker E.R. Asthma pharmacogenetics. Deborah Meyers Ed. Immunol Allergy Clin North Am 25 4 (2005) 723-742
5. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348 (2003) 538-549
6. Hall I.P. Pharmacogenetics of asthma. Eur Respir J 15 (2000) 449-451
7. GINA 2006 National Heart Lung and Blood Institute; National Institute of Health. Global Strategy for Asthma Management and Prevention: Global Initiative for Asthma (GINA). 2006 Update. Available at: http://www.ginasthma.org. Accessed July 20, 2007.
8. Stolley P.D. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis 105 (1972) 883-890
9. Grainger J., Woodman K., Pearce N., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 46 (1991) 105-111
10. Pearce N., Beasley R., Crane J., et al. End of the New Zealand asthma mortality epidemic. Lancet 345 (1995) 41-44
11. Pearce N., Burgess C., Crane J., et al. Fenoterol, asthma deaths, and asthma severity. Chest 112 (1997) 1148-1150
12. Sears M.R., Taylor D.R., Print C.G., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336 (1990) 1391-1396
13. Spitzer W.O., and Buist A.S. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 45 (1990) 645-646
14. Suissa S., Ernst P., Boivin J.F., et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 149 (1994) 604-610
15. Drazen J.M., Israel E., Boushey H.A., et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma clinical research network. N Engl J Med 335 (1996) 841-847
16. Castle W., Fuller R., Hall J., et al. Severent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306 (1993) 1034-1037
17. Nelson H.S., Weiss S.T., Bleecker E.R., et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
18. Salpeter S.R., Buckley N.S., Ormiston T.M., et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
19. Anderson H.R., Ayres J.G., Sturdy P.M., et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 330 (2005) 117
20. Walters E.H., and Walters J. Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment. Cochrane Database Syst Rev (2003) CD001285
21. Ni Chronin M., Greenstone I.R., Danish A., et al. Long acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database of Systematic Reviews (2005). Issue 4. Art. No.: CD005535 DOI:10.1002/14651858.CD005535
22. Pearlman D.S., Chervinsky P., LaForce C., et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 327 (1992) 1420-1425
23. Pauwels R.A., Lofdahl C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 (1997) 1405-1412
24. Abramson M.J., Walters J., and Walters E.H. Adverse effects of beta-agonists: Are they clinically relevant?. Am J Respir Med 2 (2003) 287-297
25. Walters E.H., Walters J.A., and Gibson M.D. Inhaled long acting beta agonists for stable chronic asthma. Cochrane Database Syst Rev (2003) CD001385
26. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
27. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
28. Kobilka B.K., Frielle T., Dohlman H.G., et al. Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions. J Biol Chem 262 (1987) 7321-7327
29. Kobilka B.K., Dixon R.A., Frielle T., et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A 84 (1987) 46-50
30. Meyers D.A., Postma D.S., Stine O.C., et al. Genome screen for asthma and bronchial hyperresponsiveness: interactions with passive smoke exposure. J Allergy Clin Immunol 115 (2005) 1169-1175
31. Xu J., Postma D.S., Howard T.D., et al. Major genes regulating total serum immunoglobulin E levels in families with asthma. Am J Hum Genet 67 (2000) 1163-1173
32. Xu J., Meyers D.A., Ober C., et al. Genomewide screen and identification of gene-gene interactions for asthma-susceptibility loci in three U.S. populations: collaborative study on the genetics of asthma. Am J Hum Genet 68 (2001) 1437-1446
33. Ober C., Cox N.J., Abney M., et al. Genome-wide search for asthma susceptibility loci in a founder population. The Collaborative Study on the Genetics of Asthma. Hum Mol Genet 7 (1998) 1393-1398
34. Reihsaus E., Innis M., MacIntyre N., et al. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 8 (1993) 334-339
35. Hawkins G.A., Tantisira K., Meyers D.A., et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 174 (2006) 1101-1109
36. Green S.A., Turki J., Innis M., et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33 (1994) 9414-9419
37. Green S.A., Turki J., Bejarano P., et al. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 13 (1995) 25-33
38. Drysdale C.M., McGraw D.W., Stack C.B., et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 97 (2000) 10483-10488
39. Moore P.E., Laporte J.D., Abraham J.H., et al. Polymorphism of the beta(2)-adrenergic receptor gene and desensitization in human airway smooth muscle. Am J Respir Crit Care Med 162 (2000) 2117-2124
40. Green S.A., Cole G., Jacinto M., et al. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268 (1993) 23116-23121
41. McGraw D.W., Forbes S.L., Kramer L.A., et al. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 102 (1998) 1927-1932
42. D'Amato M., Vitiani L.R., Petrelli G., et al. Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes. A population study. Am J Respir Crit Care Med 158 (1998) 1968-1973
43. Hall I.P., Wheatley A., Wilding P., et al. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345 (1995) 1213-1214
44. Hall I.P., Blakey J.D., Al Balushi K.A., et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 368 (2006) 771-779
45. Hancox R.J., Sears M.R., and Taylor D.R. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J 11 (1998) 589-593
46. Holloway J.W., Dunbar P.R., Riley G.A., et al. Association of beta2-adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy 30 (2000) 1097-1103
47. Kotani Y., Nishimura Y., Maeda H., et al. Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J Asthma 36 (1999) 583-590
48. Litonjua A.A., Silverman E.K., Tantisira K.G., et al. Beta 2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest 126 (2004) 66-74
49. Ramsay C.E., Hayden C.M., Tiller K.J., et al. Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway responsiveness. Clin Exp Allergy 29 (1999) 1195-1203
50. Turki J., Pak J., Green S.A., et al. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 95 (1995) 1635-1641
51. Wilson A.M., Gray R.D., Hall I.P., et al. The effect of beta2-adrenoceptor haplotypes on bronchial hyper-responsiveness in patients with asthma. Allergy 61 (2006) 254-259
52. Summerhill E., Leavitt S.A., Gidley H., et al. beta(2)-adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. Am J Respir Crit Care Med 162 (2000) 599-602
53. Dewar J.C., Wheatley A.P., Venn A., et al. Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy 28 (1998) 442-448
54. Contopoulos-Ioannidis D.G., Manoli E.N., and Ioannidis J.P. Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 115 (2005) 963-972
55. Thakkinstian A., McEvoy M., Minelli C., et al. Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162 (2005) 201-211
56. Silverman E.K., Kwiatkowski D.J., Sylvia J.S., et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 112 (2003) 870-876
57. Woszczek G., Borowiec M., Ptasinska A., et al. Beta2-ADR haplotypes/polymorphisms associate with bronchodilator response and total IgE in grass allergy. Allergy 60 (2005) 1412-1417
58. Martinez F.D., Graves P.E., Baldini M., et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100 (1997) 3184-3188
59. Choudhry S., Ung N., Avila P.C., et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 171 (2005) 563-570
60. Taylor D.R., Epton M.J., Kennedy M.A., et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 172 (2005) 700-703
61. Cho S.H., Oh S.Y., Bahn J.W., et al. Association between bronchodilating response to short-acting beta-agonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene. Clin Exp Allergy 35 (2005) 1162-1167
62. Lima J.J., Thomason D.B., Mohamed M.H., et al. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 65 (1999) 519-525
63. Tan S., Hall I.P., Dewar J., et al. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 350 (1997) 995-999
64. Moore W.C., Bleecker E.R., Curran-Everett D., et al. For the National Heart Lung Blood Institute's Severe Asthma Research Program. Characterization of the Severe Asthma Phenotype by the NHLBI Severe Asthma Research Program. J Allergy Clin Immunol 119 (2007) 405-413
65. Taylor D.R., Drazen J.M., Herbison G.P., et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 55 (2000) 762-767
66. Israel E., Drazen J.M., Liggett S.B., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162 (2000) 75-80
67. Israel E., Chinchilli V.M., Ford J.G., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364 (2004) 1505-1512
68. Liggett S.B. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 61 (2000) 167-173
69. Wechsler M.E., Lehman E., Lazarus S.C., et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173 (2006) 519-526
70. Lazarus S.C., Boushey H.A., Fahy J.V., et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285 (2001) 2583-2593
71. Lemanske Jr. R.F., Sorkness C.A., Mauger E.A., et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 285 (2001) 2594-2603
72. Bleecker E.R., Yancey S.W., Baitinger L.A., et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 118 (2006) 809-816
73. Bleecker E.R., Postma D., Lawrance R., et al. Effect of polymorphisms in the beta 2-adrenergic receptor gene on response to longacting beta-agonist therapy. J Allergy Clin Immunol 119 (2007) S523-S524 In Press The LANCET
74. Bleecker E, Yancey S, Ortega H, et al. Chest.132; 2007. Abstract In Press Sept 2007.
75. Tantisira K.G., Small K.M., Litonjua A.A., et al. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 14 (2005) 1671-1677
76. McGraw D.W., Fogel K.M., Kong S., et al. Transcriptional response to persistent beta2-adrenergic receptor signaling reveals regulation of phospholamban, which alters airway contractility. Physiol Genomics 27 (2006) 171-177
77. Small K.M., Brown K.M., Theiss C.T., et al. An Ile to Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced beta2-adrenergic receptor stimulation. Pharmacogenetics 13 (2003) 535-541